Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
The Scottish Medicines Consortium (SMC) has accepted talquetamab (Talvey, Johnson & Johnson Innovative Medicine) for use within NHS Scotland to treat adults with relapsed and refractory multiple ...
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The development of novel T ...
A promising combination for multiple myeloma received FDA approval as a second-line therapy. The approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase (Darzalex Faspro) stipulates use in ...
FDA expanded teclistamab to combination use with daratumumab hyaluronidase-fihj in earlier-line R/R myeloma, potentially second line, after prior PI and IMiD exposure. Accelerated approval for ...
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for ...
Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.
The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). Credit: ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results